ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics N.V. director Alison Frances Lawton filed an initial ownership report listing multiple share option awards over Ordinary Shares. These options have exercise prices ranging from 1.9800 to 15.7800 and expiration dates between 2026 and 2035, all held directly.
Footnotes explain that some options are fully vested, while others vest over time. For several grants, 25% of the shares vest on January 1 of 2024, 2025, 2026, or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service to the company.
ProQR Therapeutics N.V. Chief Financial Officer Dennis Hom filed an initial ownership report showing holdings of share options over Ordinary Shares. He reports options covering 750,000 shares at an exercise price of $1.66 expiring on April 30, 2035 and options over 250,000 shares at $2.02 expiring on December 31, 2035, with vesting beginning in 2026 and 2027 and continuing in quarterly installments, subject to his continued service.
ProQR Therapeutics N.V. director Theresa Heggie filed an initial ownership report showing option-based and share holdings in the company. She directly holds several "Share Option (Right to Buy)" awards on Ordinary Shares, including 100,000 underlying shares at an exercise price of $6.73 expiring on October 31, 2033, alongside other options with exercise prices ranging from $0.67 to $9.91 and expirations through 2035. She also directly holds 43,623 Ordinary Shares. Footnotes state that one option grant is fully vested and others vest 25% on specified dates with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.
ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings. The Form 3 lists multiple options to purchase ordinary shares at fixed exercise prices, with expiration dates ranging from 2029 through 2035.
One option grant is noted as fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to his continued service. The filing reports holdings only and does not show any recent share purchases or sales.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer has filed an initial ownership report listing a series of share options over Ordinary Shares. These options carry exercise prices between $0.66 and $15.78 per share, with expirations from 2026 through 2035. The filing shows existing option holdings only, with no open-market purchases or sales reported.
ProQR Therapeutics N.V. director Begona Carreno-Gomez has reported existing holdings of five share option awards over Ordinary Shares. These options carry exercise prices of $0.95, $1.98, $2.02, $2.65 and $3.41 per share, with underlying amounts of 3,565, 23,489, 25,192, 22,128 and 22,903 Ordinary Shares and expirations between October 31, 2032 and December 31, 2035. For each grant, 25% of the shares vest on specified dates from November 1, 2023 through January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to her continuous service.
ProQR Therapeutics N.V. director Shannon James Samuel filed an initial Form 3 reporting his equity holdings in the company. The filing lists multiple employee share options over ordinary shares with exercise prices ranging from $1.9800 to $15.7800 and expirations between 2026 and 2035, along with directly held ordinary shares.
The Form 3 shows direct ownership of 61,538 ordinary shares of ProQR Therapeutics and a series of vested and time-vested options that continue to vest in quarterly installments, subject to his continuous service with the company.
ProQR Therapeutics N.V. provides its Annual Report on Form 20-F for the year ended December 31, 2025, detailing a strategic focus on its Axiomer RNA editing platform. The company reports a net loss of €42.184 million in 2025 and an accumulated deficit of €467.506 million, reflecting continued heavy investment in R&D.
As of December 31, 2025, ProQR held €92.413 million in cash and cash equivalents and estimates this will fund operations into mid‑2027. The report notes that clinical development for legacy ophthalmology programs has ceased or been sold, while a Phase 1 trial of lead candidate AX‑0810 in healthy volunteers began in December 2025 for cholestatic diseases.
Management emphasizes significant ongoing risks typical for early‑stage biotech, including substantial future capital needs, regulatory uncertainty around novel RNA editing technology, reliance on third‑party collaborators and manufacturers, and extensive operational, ESG, geopolitical and intellectual property risks that could materially affect future results.
ProQR Therapeutics N.V. reported full-year 2025 results and a business update centered on its Axiomer RNA editing platform. Lead program AX-0810 for cholestatic diseases is in an ongoing Phase 1 trial, with target engagement data expected in the first half of 2026.
The company advanced its broader pipeline by selecting development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, and earned $4.5 million in milestones from its collaboration with Eli Lilly during 2025. Management highlighted continued execution of the Lilly partnership into 2026.
Financially, ProQR ended 2025 with cash and cash equivalents of approximately €92.4 million, down from €149.4 million a year earlier. Net cash used in operating activities was €52.8 million. Research and development costs were €44.7 million and general and administrative costs were €15.1 million. Net loss for 2025 was €42.2 million, or €0.40 per diluted share.
ProQR Therapeutics reported planned changes to its Board of Directors. Co-founder Dinko Valerio and director Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting as their terms conclude.
The company has engaged an executive search firm to identify new Board candidates to support its long-term strategy, governance and succession planning as it advances clinical programs based on its proprietary Axiomer™ RNA editing technology platform.